78P Clinical outcomes with atezolizumab plus bevacizumab (AB) or lenvatinib (L) in hepatocellular carcinoma (HCC). (December 2022) - Persano, M.; Rimini, M.; Cascinu, S.; Scartozzi, M.; Casadei Gardini, A.